2021
DOI: 10.1186/s13046-021-02052-z
|View full text |Cite|
|
Sign up to set email alerts
|

RETRACTED ARTICLE: Ethaselen synergizes with oxaliplatin in tumor growth inhibition by inducing ROS production and inhibiting TrxR1 activity in gastric cancer

Abstract: Background Oxaliplatin is one of the most commonly used chemotherapeutic agent for the treatment of various cancers, including gastric cancer. It has, however, a narrow therapeutic index due to its toxicity and the occurrence of drug resistance. Hence, it is of great significance to develop novel therapies to potentiate the anti-tumor effect and reduce the toxicity of oxaliplatin. In our previous study, we demonstrated that ethaselen (BBSKE), an inhibitor of thioredoxin reductase, effectively i… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2

Citation Types

0
2
0

Year Published

2022
2022
2024
2024

Publication Types

Select...
6

Relationship

0
6

Authors

Journals

citations
Cited by 6 publications
(2 citation statements)
references
References 48 publications
(47 reference statements)
0
2
0
Order By: Relevance
“…The production of ROS can activate JNK/P38 signal, thus inducing GC cell apoptosis. 24 In addition, one study found that ROS production can inhibit YAP expression and thereby activate JNK signalling. 25 Therefore, the function of JNK in GC requires more research.…”
Section: Discussionmentioning
confidence: 99%
“…The production of ROS can activate JNK/P38 signal, thus inducing GC cell apoptosis. 24 In addition, one study found that ROS production can inhibit YAP expression and thereby activate JNK signalling. 25 Therefore, the function of JNK in GC requires more research.…”
Section: Discussionmentioning
confidence: 99%
“…Finally, because TrxR1 is an important and validated drug target for cancers ( Arnér, 2017 ; Busker et al, 2020 ; Hasan et al, 2022 ) and other human diseases, including Rheumatoid arthritis ( Duan et al, 2022 ) and neurodegeneration ( Wang et al, 2022 ), the system we developed here will not only be a valuable tool for studying TrxR1 biology in human cells, but also represents a novel platform to screen inhibitors of TrxR1. Since TrxR1 inhibitors have already found application in clinical settings ( Sachweh et al, 2015 ; Zhang et al, 2021 ), our approach will facilitate applications in developing the next generation of therapeutics to target TrxR1 activity in human diseases.…”
Section: Discussionmentioning
confidence: 99%